arrow
N

Namir Shaabani

university of duisburg essen
H指数:24
被引数:2,444

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19 (vol 5, pg 42, 2024 )
MED
IF11.8
2024-02-011
OA
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
MED
IF11.8
2024-01-019
OA
The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2
2023-09-1810
OAAI
Broadening a SARS-CoV-1-neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution
2023-08-156
OA
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants
MED
IF11.8
2022-10-018
OAAI
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals

基于boceprevir的主要蛋白酶抑制剂作为SARS-CoV-2抗病毒药物的系统探索

2022-10-0133
OAAI
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals

基于醛的三肽基主要蛋白酶抑制剂作为SARS-CoV-2抗病毒药物的多管齐下评估

2022-10-0127
OAAI
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection

ACE2的靶向蛋白S-亚硝基化抑制SARS-CoV-2感染

2022-09-2918
OA
A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

人类抗体揭示了 β-冠状病毒刺突蛋白上的保守位点,并赋予了抵抗SARS-CoV-2感染的保护

2022-03-23119
OAAI
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
2021-06-0390
OAAI
Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2
2021-05-0118
OAAI
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology
2020-03-3011
OAAI